MEP of the week

Lobby organisation

AstraZeneca PLC

Business / industry · Health & pharma · HQ: United Kingdom · Transparency Register entry

As of 9 September 2026, AstraZeneca PLC appears in 92 declared MEP meetings (48 different MEPs), most often with European People's Party.

92
declared meetings
with current MEPs
48
MEPs met
€800,000/yr
declared lobbying spend
self-reported to the register
4.3
lobbyists
full time equivalent

In their own words

“AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.”

Stated goals from the organisation's own Transparency Register filing.

Who they meet, and when

Which groups they meet

Share of this organisation's 92 declared meetings, by the meeting MEP's political group.

European People's Party3538%
Socialists & Democrats2426%
Renew Europe2022%
European Conservatives & Reformists67%
Greens/EFA67%
Patriots for Europe11%

Meetings by year

Declared meetings per calendar year, 2020–2026. Bar length is relative to its busiest year (22 in 2024).

2020
2
2021
11
2022
6
2023
12
2024
22
2025
21
2026
18

Group is each MEP's current political group, not necessarily the one they sat with at the time. Shares are rounded to whole percent.

The MEPs they meet most

Nicolás González Casares
6 meetings · S&D
Tomislav Sokol
5 meetings · EPP
Tiemo Wölken
4 meetings · S&D
Jessica Polfjärd
4 meetings · EPP
Karin Karlsbro
3 meetings · Renew

The 15 most recent declared meetings

DateMEPSubject
29 Jun 2026Veronika Cifrová Ostrihoňováavailability of medicines
25 Jun 2026Carlo CiccioliBiotech Act
10 Jun 2026Kristoffer StormEU Biotech Act
9 Jun 2026Heléne Fritzonkonkurrenskraft
5 May 2026Tomislav SokolHealth Policy
29 Apr 2026Tiemo WölkenBiotech Act
24 Apr 2026Stine BosseBiotech Act roundtable
22 Apr 2026Carlo CiccioliBiotech act
31 Mar 2026Ingeborg ter LaakBiotech Act
24 Mar 2026Wouter BekeEU Biotech Act I
10 Mar 2026Jörgen WarbornInternational trade
10 Mar 2026Tomislav SokolHealth Policy
10 Mar 2026Wouter BekeHow the EU can strengthen its attractiveness for long-term investment in the pharmaceutical sector, to the benefit of patients and Europe’s competitiveness
10 Mar 2026Vytenis Povilas AndriukaitisEuropean Biotech Act
3 Mar 2026Jessica PolfjärdHealth Policy

Meeting an MEP is a normal part of democratic life; the record is shown so anyone can see it.